4.8 Meeting Abstract

A multicenter, randomized, double-blind, PLB-controlled trial of Galectin-3 inhibitor (GR-MD-02) in patients with NASH cirrhosis and portal hypertension

Journal

JOURNAL OF HEPATOLOGY
Volume 68, Issue -, Pages S100-S101

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/S0168-8278(18)30420-3

Keywords

-

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available